Meeting
2013 ASCO Annual Meeting
Phase I dose escalation study of recombinant interleukin-21 (rIL-21; BMS-982470) in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with advanced or metastatic solid tumors.
Authors
Laura Quan Man Chow
University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA
Laura Quan Man Chow , Michael S. Gordon , Theodore F. Logan , Scott J. Antonia , Shailender Bhatia , John A. Thompson , Julie R. Brahmer , Gretchen Solberg , Rachel Bittner , David Fontana , Joseph Grosso , Lewis J. Cohen , Christoph Matthias Ahlers , Jon M. Wigginton , Charles G. Drake
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Immunotherapy
Track
Developmental Therapeutics
Sub Track
Immunotherapy and Biologic Therapy
Clinical Trial Registration Number
NCT01629758
Citation
J Clin Oncol 31, 2013 (suppl; abstr TPS3112)
DOI
10.1200/jco.2013.31.15_suppl.tps3112
Abstract #
TPS3112
Poster Bd #
22G
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
A phase I dose-escalation study of BGB-A317, an anti-programmed death-1 (PD-1) mAb in patients with advanced solid tumors.
First Author: Jayesh Desai
Poster
2016 ASCO Annual Meeting
A first-in-human phase I study of the anti-PD-1 antibody PDR001 in patients with advanced solid tumors.
First Author: Aung Naing
Poster
2013 ASCO Annual Meeting
Phase I dose escalation study of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with advanced hepatocellular carcinoma (HCC) with or without chronic viral hepatitis.
First Author: Bruno Sangro
Poster
2017 ASCO Annual Meeting
Phase II clinical trial of atezolizumab (A) in advanced non-small cell lung cancer (NSCLC) patients (pts) previously treated with PD1-directed therapy.
First Author: Saveri Bhattacharya